- Home
- HBIO vs NERV Comparison
HBIO vs NERV Comparison
Compare HBIO & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBIO
- NERV
- Stock Information
- Founded
- HBIO 1901
- NERV 2007
- Country
- HBIO United States
- NERV United States
- Employees
- HBIO N/A
- NERV N/A
- Industry
- HBIO Biotechnology: Laboratory Analytical Instruments
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- HBIO Industrials
- NERV Health Care
- Exchange
- HBIO Nasdaq
- NERV Nasdaq
- Market Cap
- HBIO 13.0M
- NERV 12.4M
- IPO Year
- HBIO 2000
- NERV 2014
- Fundamental
- Price
- HBIO $0.35
- NERV $1.52
- Analyst Decision
- HBIO Buy
- NERV Hold
- Analyst Count
- HBIO 2
- NERV 1
- Target Price
- HBIO $3.00
- NERV $5.00
- AVG Volume (30 Days)
- HBIO 1.1M
- NERV 5.9K
- Earning Date
- HBIO 05-12-2025
- NERV 05-13-2025
- Dividend Yield
- HBIO N/A
- NERV N/A
- EPS Growth
- HBIO N/A
- NERV N/A
- EPS
- HBIO N/A
- NERV 0.82
- Revenue
- HBIO $91,397,000.00
- NERV N/A
- Revenue This Year
- HBIO N/A
- NERV N/A
- Revenue Next Year
- HBIO $8.58
- NERV N/A
- P/E Ratio
- HBIO N/A
- NERV $1.95
- Revenue Growth
- HBIO N/A
- NERV N/A
- 52 Week Low
- HBIO $0.33
- NERV $1.15
- 52 Week High
- HBIO $4.08
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- HBIO 43.83
- NERV 40.93
- Support Level
- HBIO $0.34
- NERV $1.58
- Resistance Level
- HBIO $0.39
- NERV $1.74
- Average True Range (ATR)
- HBIO 0.06
- NERV 0.06
- MACD
- HBIO 0.02
- NERV -0.01
- Stochastic Oscillator
- HBIO 21.03
- NERV 0.00
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.